EX-99.2 3 ea159290ex99-2_lantern.htm PRESENTATION RELATING TO MAY 3, 2022 CONFERENCE CALL AND LIVE WEBINAR TO DISCUSS FINANCIAL AND OPERATING RESULTS FOR QUARTER ENDED MARCH 31, 2022

Exhibit 99.2

First Quarter 2022 Operating & Financial Results Conference Call / Webinar May 3 rd , 2022 4:30 PM Eastern Time NASDAQ :LTRN

First Quarter 2022 Earnings 7KLVSUHVHQWDWLRQFRQWDLQVIRUZDUG ORRNLQJVWDWHPHQWVZLWKLQWKHPHDQLQJRI6HFWLRQ $RIWKH6HFXULWLHV$FWRI DVDPHQGHGDQG 6HFWLRQ (RIWKH6HFXULWLHV([FKDQJH$FWRI DVDPHQGHG7KHVHIRUZDUG ORRNLQJVWDWHPHQWVLQFOXGHDPRQJRWKHUWKLQJVVWDWHPHQWV UHODWLQJWRIXWXUHHYHQWVRURXUIXWXUHILQDQFLDOSHUIRUPDQFHWKHSRWHQWLDODGYDQWDJHVRIRXU5$'5 p SODWIRUPLQLGHQWLI\LQJGUXJFDQGLGDWHV DQGSDWLHQWSRSXODWLRQVWKDWDUHOLNHO\WRUHVSRQGWRDGUXJFDQGLGDWHRXUVWUDWHJLFSODQVWRDGYDQFHWKHGHYHORSPHQWRIRXU GU XJ FDQGLGDWHVDQGDQWLERG\GUXJFRQMXJDWH$'& GHYHORSPHQWSURJUDPHVWLPDWHVUHJDUGLQJWKHGHYHORSPHQWWLPLQJIRURXUGUXJFDQ GLG DWHV DQG$'&GHYHORSPHQWSURJUDPRXUUHVHDUFKDQGGHYHORSPHQWHIIRUWVRIRXULQWHUQDOGUXJGLVFRYHU\SURJUDPVDQGWKHXWLOL]DWLRQ RI RXU 5$'5 p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Ȋ REMHFWLYH ȋ DLP ȋȊ XSFRPLQJ ȋ VKRXOGZLOOZRXOGRUWKHQHJDWLYHRIWKHVHZRUGVRU RWKHUVLPLODUH[SUHVVLRQV VKRXOGEHFRQVLGHUHGIRUZDUG ORRNLQJVWDWHPHQWV7KHUHDUHDQXPEHURILPSRUWDQWIDFWRUVWKDWFRXOGF DXVHRXU DFWXDOUHVXOWVWRGLIIHUPDWHULDOO\IURPWKRVHLQGLFDWHGE\WKHIRUZDUG ORRNLQJVWDWHPHQWVVXFKDV L WKHLPSDFWRIWKH&29Ζ' SDQGHPLF LL WKHULVNWKDWRXUUHVHDUFKDQGWKHUHVHDUFKRIRXUFROODERUDWRUVPD\QRWEHVXFFHVVIXOLLL WKHULVNWKDWZHPD\QRWE HD EOHWRVXFFHVVIXOO\ LQLWLDWHFRQGXFWRUFRQFOXGHFOLQLFDOWHVWLQJIRURUREWDLQPDUNHWLQJDSSURYDOIRURXUSURGXFWFDQGLGDWHVLY WKHULVNWK DW QRGUXJSURGXFW EDVHGRQRXUSURSULHWDU\5$'5 p $ΖSODWIRUPKDVUHFHLYHG)'$PDUNHWLQJDSSURYDORURWKHUZLVHEHHQLQFRUSRUDWHGLQWRDFRPPHUFLDO SURGXFWDQGY WKRVHRWKHUIDFWRUVVHWIRUWKLQWKH5LVN)DFWRUVVHFWLRQLQRXU$QQXDO5HSRUWRQ)RUP .IRUWKH\HDUHQGHG'HFHPEHU ILOHGZLWKWKH6HFXULWLHVDQG([FKDQJH&RPPLVVLRQRQ0DUFK <RXPD\DFFHVVRXU$QQXDO5HSRUWRQ)RUP .IRUWKH\HDU HQGHG'HFHPEHU XQGHUWKHLQYHVWRU6(&ILOLQJVWDERIRXUZHEVLWHDW ZZZODQWHUQSKDUPDFRP RURQWKH6(& VZHEVLWHDW ZZZVHFJRY *LYHQWKHVHULVNVDQGXQFHUWDLQWLHVZHFDQJLYHQRDVVXUDQFHVWKDWRXUIRUZDUG ORRNLQJVWDWHPHQWVZLOOSURYHWREHDFFXUDWH RUWKDWDQ\RWKHUUHVXOWVRUHYHQWVSURMHFWHGRUFRQWHPSODWHGE\RXUIRUZDUG ORRNLQJVWDWHPHQWVZLOOLQIDFWRFFXUDQGZHFDXWL RQLQYHVWRUV QRWWRSODFHXQGXHUHOLDQFHRQWKHVHVWDWHPHQWV$OOIRUZDUG ORRNLQJVWDWHPHQWVLQWKLVSUHVHQWDWLRQUHSUHVHQWRXUMXGJPHQWDVR IWKHGDWH KHUHRIDQGH[FHSWDVRWKHUZLVHUHTXLUHGE\ODZZHGLVFODLPDQ\REOLJDWLRQWRXSGDWHDQ\IRUZDUG ORRNLQJVWDWHPHQWVWRFRQIRUP WKH VWDWHPHQWWRDFWXDOUHVXOWVRUFKDQJHVLQRXUH[SHFWDWLRQV Forward - Looking Statements 1

Contents 01 Introduction 02 Q1 2022 Highlights 03 Scientific Progress 04 Financial Highlights 05 Q&A Speakers Panna Sharma Chief Financial Officer ΖQYHVWRU5HODWLRQV Chief Executive Officer, President and Director David Margrave Nicole Leber Chief Scientific Officer Dr. Kishor Bhatia Host

First Quarter 2022 Earnings Lantern Pharma Leveraging A.I. to reduce oncology drug development costs and improve the likelihood of success Abundance of data Proprietary A.I. platform RADR ® Accelerated timeline and reduced cost

First Quarter 2022 Earnings Australia Operation • Actively conducting multiple studies in Australia under Lantern Australian subsidiary • Takes advantage of R&D tax incentive program 5$'5 p ([SDQVLRQ ‡ 5$'5 p KDVVXUSDVVHG ELOOLRQGDWDSRLQWV ‡ 3XUVXLQJDGGLWLRQDOELRSKDUPDFROODERUDWLRQV Share Repurchases • Announced extension of existing share repurchasing program Pediatric Cancer • Initiated work with Greehey Children’s Cancer Institute at UT Health San Antonio • Early preclinical efficacy seen in initial studies +DUPRQLF Ƞ 7ULDO • Submitted IND amendment including a finalized clinical study protocol to the FDA in mid - April for Phase 2 trial • 1st patient anticipated in Summer 2022 LP - 184 • IND enabling studies progressing • IND submission targeted in Q3 2022 Brain Metastases • Presented poster and findings at AACR • Pursuing new indication for LP - 184 in a market with significant unmet clinical need Synthetic Lethality • Evidence of a synthetic lethal relationship between LP - 184 and NERD and HRD tumors 4 First Quarter 2022 Highlights

First Quarter 2022 Earnings +DUPRQLF Ƞ &OLQLFDO7ULDO Ȃ 3KDVH 7ULDOIRU/3 5 ‡ +DUPRQLF Ƞ FOLQLFDOWULDOLVD3KDVH PXOWL FHQWHUVWXG\WR HYDOXDWH/DQWHUQ ȇ VLQYHVWLJDWLRQDOGUXJ/3 ‡ SDWLHQWWZR DUPRSHQODEHO UDQGRPL]HGWULDO ‡ UDQGRPL]DWLRQLQD DOORFDWLRQUDWLRWRRQHRIWZRDUPV ‡ 7ULDOLVIRFXVHGRQ QHYHUVPRNHU SDWLHQWVZLWKUHODSVHG SULPDU\DGHQRFDUFLQRPDRIWKHOXQJDW\SHRI16&/&1RQ 6PDOO&HOO/XQJ&DQFHU ΖQDVXEVHWRI1HYHU6PRNHUSDWLHQWVIURPDODUJHU16&/&WULDO SDWLHQWVZKRUHFHLYHG/3 ZLWKFKHPRWKHUDS\VKRZHG LQFUHDVHG RYHUDOODQG \HDUSDWLHQWVXUYLYDOE\ DQG UHVSHFWLYHO\ Total expected patients 90 Patients Total expected sites 15 - 20 Sites (VWLPDWHGILUVWSDWLHQWHQUROOPHQW Summer 2022 <HDU6XUYLYDO 2YHUDOO6XUYLYDO 125% median survival increase median survival increase

First Quarter 2022 Earnings /3 Ζ1'HQDEOLQJVWXGLHV 6 Completed Ongoing Expected 6WXG\7\SH Method Results Dog non - GLP tox study NOAEL 0.3mg/kg for repeat weekly dosing (days 1, 8 and 15) At NOAEL in dogs LP - 184 PK parameters measured on dosing days 1 and 15 showed ○ t1/2 = 40 - 50 min ○ Cmax = 800 nM ○ Tmax = 5 min ○ At 0.3mg/kg some hematotoxicity observed in form of decreased counts of blood lymphocytes Analytical Method Development Completed LC - MS method development for rat/ dog plasma, and matrix/ storage/ pH/ freeze - thaw stability; precision & accuracy Standard curve: 1 - 200 ng/mL; QC levels: 1, 3, 75, 180, 200 ng/mL Study Type Method Expected completion Analytical Method Validation 30 - day stability protocols June 2022 Dog GLP 3 weekly doses (0.2, 0.4 and 0.6mg/kg) Early June 2022 6(1'UHSRUWIRUPDW WR)'$ CMC data for FDA IND filling 3KDVH /3 WULDO Targeted for Q3 Targeted for Q4

First Quarter 2022 Earnings In vitro efficacy of our drug candidate LP - 184 in brain metastases ( mets .) , • LP - 184 has activity in the primary and secondary cancers AND crosses the BBB. • Efficacy of LP - 184 may extend beyond primary brain cancers to other solid tumors that have metastasized to the brain as evidenced by in vitro efficacy in brain mets . cell lines. • LP - 184 demonstrated anti - tumor activity in brain metastases cell models from lung, skin, and breast cancers. • Data supports continued development of LP - 184 in these CNS cancer indications LP - 184 is 6X more potent than early generation EGFR TKIs in brain metastasis models from primary lung cancer 8QPHW&OLQLFDO1HHG LQ%UDLQ0HWDVWDVHV • Brain metastases in the U.S. occur in 10 - 30% of all cancer cases and are diagnosed in over 100,000 patients each year. • There is an urgent and unmet clinical need for novel therapies for brain mets due to a current lack of novel agents that can cross the blood brain barrier (BBB). $ 9 Billion US Market Potential Estimated

First Quarter 2022 Earnings /DQWHUQHVWDEOLVKHGDQ$XVWUDOLDQVXEVLGLDU\ 8 Subsidiary will allow: o Lantern to take advantage of Australia’s R&D Tax Incentive program, which provides tax offsets for eligible R&D expenditures o Lantern to conduct preclinical and IND enabling studies, many of which are already underway o Increases financial flexibility and improves capital efficiency for ongoing R&D activity /DQWHUQ3KDUPD$XVWUDOLD3W\/WGD/DQWHUQVXEVLGLDU\ZDVHVWDEOLVKHGLQ$XVWUDOLDLQ6HSWHPEHU Established Australia subsidiary to take advantage of Australia’s Research & Development Tax Incentive

First Quarter 2022 Earnings RADR ® Surpassed 20 Billion Datapoints 9 2019 2020 Apr. 2021 Dec. 2021 2022* Ēĕ 8 100M 275M 450M 1.1 B ĔĽĖſ 10.4 B 2XUJRDOLVWRH[SDQG 5$'5WR ELOOLRQGDWDSRLQWV GXULQJ 1. Focus on automation of data acquisition 2. Improve data user interface to other analytical tools and containers 3. Improve tagging of metadata 4. Enter into additional value - based biopharma collaborations Future Goals For A.I. Platform

First Quarter 2022 Earnings LP - 300 Mechanism of action 3URWHLQ'HJUDGDWLRQ Panel A : LP - 300 adduct at Cys 1235 Panel B : LP - 300 adduct at Cys 1156 Panel C : Molecular surface of ALK with the LP - 300 - derived adduct at Cys 1156 ( yellow highlight ) Panel D : Binding site of the LP - 300 - derived adduct at Cys 1235 ( yellow highlight ) LP - 300 can degrade NSCLC proteins such as EGFR, ALK and ROS via cysteine modification (OHFWURQGHQVLW\PDSVVKRZLQJ/3 GHULYHG DGGXFWVRQ$/. • LP - 300 in previous clinical trials has been well tolerated in around 1,000 people . • In a subset of Never Smoker patients from a larger NSCLC trial, patients who received LP - 300 with chemotherapy showed increased overall and 2 - year patient survival by 91% and 125%, respectively. A B C ' LP - 300 Target Modulation /3 PRGXODWHVWDUJHWVZLWKLQNH\VLJQDOLQJSDWKZD\VLQ16&/& • Receptor Tyrosine Kinases involved in proliferation/ survival signaling pathways ( EGFR, ALK, ROS 1 ) • Enzymes critical for DNA synthesis and repair ( ERCC 1 , RNR 1 , RNR 2 ) • Enzymes and proteins important in regulating cellular redox status ( TRX, PRX, GRX, PDI ) LP - 300 modulates : LP - 300 molecule 10

First Quarter 2022 Earnings LP - 184 IND enabling studies 11 &RPSOHWHG Ongoing Expected 6WXG\7\SH Method Results Dog non - GLP tox study NOAEL 0.3mg/kg for repeat weekly dosing (days 1, 8 and 15) At NOAEL in dogs LP - 184 PK parameters measured on dosing days 1 and 15 showed ○ t1/2 = 40 - 50 min ○ Cmax = 800 nM ○ Tmax = 5 min ○ At 0.3mg/kg some hematotoxicity observed in form of decreased counts of blood lymphocytes Analytical Method Development Completed LC - MS method development for rat/ dog plasma, and matrix/ storage/ pH/ freeze - thaw stability; precision & accuracy Standard curve: 1 - 200 ng/mL; QC levels: 1, 3, 75, 180, 200 ng/mL Study Type Method Expected completion Analytical Method Validation 30 - day stability protocols June 2022 Dog GLP 3 weekly doses (0.2, 0.4 and 0.6mg/kg) Early June 2022 SEND report format to FDA CMC data for FDA IND filling Phase 1 LP - 184 trial Targeted for Q3 7DUJHWHGIRU4

First Quarter 2022 Earnings In vitro efficacy of our drug candidate LP - 184 in brain metastases ( mets .) , 12 • LP - 184 has activity in the primary and secondary cancers AND crosses the BBB. • Efficacy of LP - 184 may extend beyond primary brain cancers to other solid tumors that have metastasized to the brain as evidenced by in vitro efficacy in brain mets . cell lines. • LP - 184 demonstrated anti - tumor activity in brain metastases cell models from lung, skin, and breast cancers. • Data supports continued development of LP - 184 in these CNS cancer indications LP - 184 is 6X more potent than early generation EGFR TKIs in brain metastasis models from primary lung cancer Unmet Clinical Need in Brain Metastases • Brain metastases in the U.S. occur in 10 - 30% of all cancer cases and are diagnosed in over 100,000 patients each year. • There is an urgent and unmet clinical need for novel therapies for brain mets due to a current lack of novel agents that can cross the blood brain barrier (BBB). %LOOLRQ 860DUNHW3RWHQWLDO Estimated

First Quarter 2022 Earnings LP - 184 shows exquisite sensitivity in NERD as well as HRD cancers 13 LP - 184 in HRD cancers LP - 184 in NERD cancers • NERD tumors are nucleotide excision repair deficient tumors whose phenotype is a result of mutations in genes responsible for excision DNA repair - these include but not limited to - ERCC1 , ERCC3, ERCC4, ERCC5, ERCC6, RAD50, ATR, ATM, MRE, CSB , XPD etc. • Mutant cell lines deficient in the Nucleotide Excision Repair (NER) pathway were more sensitive to LP - 184 than the parent cell line ‡ +5' DUH +RPRORJXV UHFRPELQDWLRQGH΋FLHQWWXPRUVDQG FDUU\PXWDWLRQVLQJHQHVVXFKDV %5&$ %5&$ 3$/% %5,3 )$1&$ HWF ‡ /3 WUHDWPHQWUHVXOWHGLQFRPSOHWHWXPRUUHJUHVVLRQLQD 3';PRGHORI71%&WKDWLV+5GH΋FLHQWDQGUHVLVWDQWWR 3$53LQKLELWRUVDQGGR[RUXELFLQF\FORSKRVSKDPLGH

First Quarter 2022 Earnings Financial Update Q1 2022 14 2022 2021 Operating expenses : General and administrative 1,406,160 1,173,258 Research and development 2,660,237 1,279,037 Total operating expenses 4,066,397 2,452,295 Loss from operations (2,452,295) Interest + Other income, net (55,377) - NET LOSS $ (4,121,774) $ (2,452,295) Net loss per common share, basic and diluted $ (0.38) $ (0.24) Weighted Avg. Common Shares Outstanding - Basic and Diluted 10,875,777 10,074,623 3/31/2022 12/31/2021 Cash and Marketable Securities $ 65,216,479 $ 70,725,447 Prepaid Expenses & Other Current Assets $ 2,446,679 $ 1,990,953 Total Assets $ 68,402,517 $ 73,950,477 Total Liabilities $ 3,087,145 $ 2,379,057 Total Stockholders’ Equity $ 65,315,372 $ 71,571,420 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended March 31, We believe our solid financial position will fuel continued growth and evolution of our RADR ® A.I. platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted product and collaboration opportunities in a capital efficient manner. ” “ (unaudited) (unaudited)

First Quarter 2022 Earnings LTRN Share Information 15 March 31, 2022 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 10,830,947 Warrants 177,998 Options (Employees, Management and Directors) 890,826 Fully Diluted Shares Outstanding 11,899,771 Date Shares Repurchased Average Price Total Paid including Commission FY 2021 121,490 $7.71 $939,666 Three months ended March 31, 2022 353,667 $6.86 $2,482,286 Total 475,157 $7.08 $3,421,952 Up to $7 Million is authorized for repurchase under Lantern’s repurchase program, of which approximately $3.6 Million remains av ailable for future purchases.

First Quarter 2022 Earnings Maria Maccecchini , Ph.D. was nominated for election to Lantern’s Board of Directors 16 Maria L. Maccecchini , Ph.D. Founder, President, Chief Executive Officer, and director of Annovis Bio ( NYSE: ANVS ) New Director Nominee Dr. Maccecchini will be presented alongside a slate of five existing Directors at Lantern's upcoming Annual Meeting to be held on June 8, 2022.

First Quarter 2022 Earnings Upcoming Events 9th Drug Discovery Strategic Summit Speaker: Kishor Bhatia MAY 9 13 Strategic Investment Conference Speaker: Panna Sharma MedVentures Conference 2022 Speaker: Panna Sharma 19 Augmented intelligence in drug discovery Xchange east coast, Speaker: Panna Sharma JUNE 23 Bioinformatics Strategy Meeting East Coast USA 2022 Speaker: Panna Sharma 7 World Orphan Drug Congress USA 2022 Speaker: Panna Sharma LD Micro Invitational Speaker: Panna Sharma JULY 11 18 17

First Quarter 2022 Earnings Key Corporate Objectives and Milestones 18 Ɣ /DXQFKRI 7KH+DUPRQLF Ƞ 7ULDO 3K FOLQLFDOWULDOIRU/3 LQ16&/& Ɣ $GYDQFH/3 FOLQLFDOGHYHORSPHQW Ɣ /DXQFK3K FOLQLFDOWULDOIRU/3 LQ JHQRPLFDOO\ GHILQHG VROLGWXPRUV Ɣ 'HVLJQ3K FOLQLFDOWULDOIRU/3 LQ*%0 Ɣ 3URJUHVV/3 LQ$757WRZDUGV3K FOLQLFDOWULDO Ɣ $GYDQFHSHGLDWULFFDQFHUGUXJGHYHORSPHQWSURJUDP Ɣ $GYDQFH$'&SUHFOLQLFDOVWXGLHVWRVXSSRUWIXWXUH3KDVH ODXQFK Ɣ ([SORUHSRWHQWLDOFRPELQDWLRQVIRU/3 /3 /3 /3 ZLWK RWKHUH[LVWLQJDSSURYHGGUXJV Ɣ 6WUDWHJLFDOO\JURZ5$'5 p $ΖSODWIRUPWR ELOOLRQGDWDSRLQWV Ɣ ([SORUHOLFHQVLQJDQGSDUWQHUVKLSRSSRUWXQLWLHV 2022 Objectives and Milestones

Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1 - 972 - 277 - 1136 www.lanternpharma.com @LanternPharma